Targeting peripheral κ-opioid receptors for the non-addictive treatment of pain
Authors:
Open Access
- 2 September 2019
- journal article
- Published by Taylor & Francis in Future Drug Discovery
- Vol. 1 (2)
Abstract
Drug addiction to prescription μ-opioid agonists used in the setting of pain is a major public health threat, affecting millions of Americans. κ-opioid agonists (KOAs) may serve as a possible solut...Keywords
Funding Information
- National Institutes of Health (DA-036398, NS-090629, MH-65099)
This publication has 14 references indexed in Scilit:
- Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in ratsEuropean Journal of Pharmacology, 2019
- Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptidesPeptides, 2019
- Design, synthesis and biological profile of mixed opioid agonist/N-VGCC blocker peptidesNew Journal of Chemistry, 2018
- Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral PainThe Open Medicinal Chemistry Journal, 2013
- The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse LiabilityACS Chemical Neuroscience, 2012
- Pain as a global public health priorityBMC Public Health, 2011
- Tapentadol approved as pain relieverAmerican Journal of Health-System Pharmacy, 2009
- Effect of Exogenous Kappa-Opioid Receptor Activation in Rat Model of Myocardial InfarctionJournal of Cardiovascular Pharmacology, 2004
- Peripherally Restricted Opioid Agonists as Novel Analgesic AgentsCurrent Pharmaceutical Design, 2004
- ORL1, a novel member of the opioid receptor familyFEBS Letters, 1994